Latest From Biocodex
GW Pharmaceuticals is pressing on with plans to launch its epilepsy treatment Epidyolex in the EU, starting with France and Germany.
Drug will meet pent-up demand in Europe for clinically proven cannabis-based medicine for hard-to-treat epilepsy.
Keeping Track: NME Approvals For Evenity And Balversa; Non-NME Approvals For Dovato And Keytruda; But An RTF For Fintepla
France's Supplement Market in 2018: Demand For Probiotics and Natural Alternatives Drives Sales Growth
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Western Europe
- Parent & Subsidiaries
- Senior Management
- Contact Info
Phone: 1 46 63 83 13
7, avenue Gallieni
Gentilly , 94257
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.